<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">This is a country-specific analysis of an international, multicenter, retrospective and prospective observational study. The study design was as described elsewhere [
 <xref ref-type="bibr" rid="CR17">17</xref>]. Briefly, NHL patients undergoing ASCT and qualifying as poor mobilizers, i.e., CD34+ count &lt; 20 × 10
 <sup>6</sup> cells/kg after mobilization, were enrolled from two-time periods: prior to approval of plerixafor (July 2009, pre-plerixafor era) and after approval of plerixafor (plerixafor era). The study was conducted at ten European centers, four of them being in Germany. Patients were eligible if 18 years and older with a diagnosis of NHL.
</p>
